To Inhale or Inject; that is the Question (NASDAQ:MNKD)

When you take a look at MannKind Corporation (NASDAQ:MNKD) there are three things that stand out: 1) it is a ‘development’ company; 2) its primary product called AFREZZA could be a game changer; and 3) bio-tech and pharmaceuticals are always a “Long-Term” play.

Lots of financial observers have a love-hate relationship with MNKD: it seems in a nutshell they A) love the potential of the product from a patient’s point of view and the size of the potential market, and B) are tiring in waiting for an FDA approval to get AFREZZA to market and wonder can the Company handle it when and if the time comes to disperse the product globally.

Understandable.

Bio-tech and pharma investors know that the industry is a high risk; high reward play and investment propositions have to based on, once again; the long-term. MNKD is no exception.

To inhale or inject…

MannKind’s AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes. The idea here is that instead of sticking a needle in and injecting insulin; a quick inhalation from the MNKD inhaler and you’re done. The convenience is staggering.

And so is the conceivable market that pundits and investors see… 350 million people around the world with type I and II diabetes. And, and… with a thumbs up from the FDA; the only inhalable insulin available. Plus, plus… the AFREZZA technology could lead to licensing opportunities for other drugs that currently only available via injections.

With an FDA approval, expected to be offered or not sometime in 2013, I think the commercialization of such a product would find a lot of “Big-Cap” pharmaceuticals willing to work out ‘a deal.’

MannKind will release its 2012 second quarter financial results tomorrow, on Tuesday, August 7, 2012 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 9:00 AM (Eastern Time).

I have no idea what the numbers will be, but I’m guessing they will be typical for a development company at this stage of the game; some good and some weak (remember we’re talking bio-tech and pharmaceuticals here).
Shares today are trading in the $2.17 range. MNKD has a 52-week high-low of $1.57 to $3.95.

http://www.smallcapnetwork.com/To-Inhale-or-Inject-that-is-the-Question-NASDAQ-MNKD/s/via/14/article/view/p/mid/1/id/939/